I was not trying to specifically relate their need for new and innovated products to SRPT. However, with all of the patent expirations (especially Lipitor),if ETEP and the exon skipping domain is clinically and commercially viable, then the Macro's will be hunting down the up and coming Micro's. As others have stated on this thread, many Pharma's are short cutting the lengthy and expensive R&D (preclinical to approval, 5 plus years, risk of failure and very expensive with the P1 through P3 trials). Rather, by acquisitions of promising later stage drugs and platforms, the smaller company has already taken the risks and done the grunt work and funded the high risk phases of development.
SRPT seems to fit.
Now Pfizer’s management team is looking for products or a business to help make up for patent expirations of what once were blockbuster drugs. And a deal could be big or small.
“I don’t think we’re looking at limitations on size,” Read said in an interview. “With size sometimes comes complexity
Remember the old garage doors openers that were dependent on the coiled spring. If they go, serious harm to anyone nearby. The shorts are standing next to an imminent uncoiling night mare.
We were on the phone at the same time during this crisis. I told him what he posted and I did not like the fact the he gave names and locations for family confidentially purposes. If you continue to persecute my family and create animosity....you are responsible. you have already tormented us to the 10th degree. You make your choice as to how you would like to make my family suffer. I told Pearsby to hold off on his posts for at least a month....YOU..need to do the same!! She is dead...feed on it if it makes you feel better. However, it will not make me feel better....SHE IS DEAD #$%$ HOLE...Take a screen shot of this!
6 years on this board...minimum. More than 90% of investors....SHE IS DEAD....go for it!
I have been long for six years...May be. Lost tract. Check my history for the last 5 years...pro CTSO. I lost a close friend and family member and you are anextremely insensitive SOB.
LOL...I was literally going to post the exact same thing as you! I am sensing an ICPT break out and have nothing but hope and faith in Etep. However, now that both of us have gone out on a limb, we can fall together if wrong. GLTA
Bio, thanks for all your excellent DD and input on this board. What I just don't get, is how this is any different than 6 statins and 11 ACE inhibitors, treating hypercholesterolemia and Hypertension, respectively. Both groups of drugs have very similar physiological targets and MOA's. Again, Drisa and Etep seem to be more different than the previously mentioned. Additionally, we are talking about an unmet disease state where even similar targets and MOA's should be further scrutinized by differential analysis by comparing pharmacodynamics, pharmacokinetics, clinical efficacy and safety. I just can't see this to be an issue, otherwise we would have only one drug for every disease state. JMHO
I believe you have it backwards. Conversely, the silence will play well into an unprecedented PR announcing strong safety trial results, impressive dystrophin data and Positive interim progress on the P3 data. An unprecedented announcement will cause a gap up and massive short covering. Also, there is the potential of partnerships (other platforms), BO rumors and the official NDA application. Possibly, a granted AA sooner than the market is anticipating. This silence will be shattered very soon. GLTY
He has an appointment tomorrow in Ann Arbor. He started out with oral cancer. He was successfully treated with Chemo and radiation and went into full remission. We all thought goodbye cancer. Two years later, the cancer metastasized into his lungs and other organs and is put him into stage 4/5 prognosis. He has a strong faith, great values and is a college head football coach who is a magnificent role model and mentor. His Faith, character, work ethic, life style and selflessness is beyond belief. So many young men have benefited from his impact in their lives. He is only 54, never chewed, smoked or drank. Please pray for him. His appointment at U of M is focused around Keytruda intervention. I informed his wife to inquire about the combination of electroporation and Keytruda, as he may be a candidate. She is a Dentist and has excellent understanding of medicine. I told her the physician may not know about electroporation. She told me she would ask about that potential combination. I will let you all know about the physician feedback. He is basically Hospice status, so I believe proactive aggressive intervention is necessitated.
Yes it will be, but not for you. This thing is a saw tooth/channeling upward trajectory in a controlled matter....until a major breakout. Today SRPT is a bobber on the receding market tide. The bobber will soon ride the tsunami.
Yes. This thing is a saw tooth/channeling upward trajectory in a controlled matter....until a major breakout. Today SRPT is a bobber on the receding market tide.
This has been an undervalued coiled spring for two years...time to uncoil. The safety trial is somewhat transparent and near completed (must not be any surprises), they know the dystrophin data sets and the initial P3 must be going well. All phases are in positive motion...enjoy the ride and shorts should cover. Best of all, the kids will have hope for the first time in DMD history...then the door will open for additional exons and perhaps treating multiple unmet disease states in the future. Be careful of an unprecedented BO in the next weeks, which I DO NOT want. KG
I believe the safety trial and dystrophin data will be reinforcing what us longs already know. We are getting closer to a substantial breakout. For now, channeling higher each few days. GLTA
They have been adding additional sites since that enrollment update. I expect full enrollment ahead of forecast. I am guessing mid October to Mid November range.
I have placed my bet that Etep will make a difference in the DMD disease state. I have also placed my bet that the exon skipping domain could bring further scientific breakthrough treatments for a variety of unmet disease states. So far, things look quite promising. If there were safety issues with the P3, safety trial and other exon trials we would know by now. The safety trial is close to completion. I admit, I am too emotionally attached to this stock due to the children. May Etep be the answer, or at least the first big step!
If we get AA and all exons get the green light for a variety of disease states, you may be surprised. The float is 4X what ICPT was, which will limit it the upward trend, but I am only talking about if all the components come together,,,which is possible. The ICPT investors with their P2 trial interim surprise probably never expected 38 to 490 gap up. Keep the faith. This disease state has been untreatable since the Jerry Lewis days and far prior to that. If exon skipping is approved, don't be shocked by the astronomical reception by the world and the market.
Phenomenal move! If Dystrophin validation is solid, 24 week safety data reaffirming safety and maybe parental and objective efficacy trends. I realize the safety trial is powered towards safety, but if there are responders...watch out above! The FDA does listen to the parents. Also, we will have a fairly large cohort of P3 patients by ADCOM timeframe for even more data, reassurance and validation. This is a coiled spring in the mid 20's.